{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T06:02:32Z","timestamp":1788328952529,"version":"build-2803163510"},"reference-count":52,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2004,6,1]],"date-time":"2004-06-01T00:00:00Z","timestamp":1086048000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,6,1]],"date-time":"2004-06-01T00:00:00Z","timestamp":1086048000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2004,6]]},"DOI":"10.1124\/jpet.103.062414","type":"journal-article","created":{"date-parts":[[2004,5,25]],"date-time":"2004-05-25T22:48:09Z","timestamp":1085525289000},"page":"921-935","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["S32504, a Novel Naphtoxazine Agonist at Dopamine D3\/D2 Receptors: II. Actions in Rodent, Primate, and Cellular Models of Antiparkinsonian Activity in Comparison to Ropinirole"],"prefix":"10.1016","volume":"309","author":[{"given":"Mark J.","family":"Millan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Di Cara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey N.","family":"Joyce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Brotchie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"McGuire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Crossman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lance","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Jenner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Gobert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Louis","family":"Peglion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauricette","family":"Brocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.103.062414_bib1","doi-asserted-by":"crossref","unstructured":"Alcantara AA, Chen V, Herring BE, Mendenhall JM, and Berlanga M (2003) Localization of dopamine D2 receptors on cholinergic interneurons of the dorsal striatum and nucleus accumbens of the rat. Brain Res 986: 22-29.","DOI":"10.1016\/S0006-8993(03)03165-2"},{"key":"10.1124\/jpet.103.062414_bib2","doi-asserted-by":"crossref","unstructured":"Araki T, Tanji H, Fujihara K, Kato H, Imai Y, Mizugaki M, and Itoyama Y (2000) Sequential changes of cholinergic and dopaminergic receptors in brains after 6-hydroxydopamine lesions of the medial forebrain bundle in rats. J Neural Transm 107: 873-884.","DOI":"10.1007\/s007020070039"},{"key":"10.1124\/jpet.103.062414_bib3","unstructured":"Bennett JP, Carvey PM, Hinds TR, Johnson RD, Le WD, Phillips W, Sethy VH, Vincenzi FF, and Youdim MB (2001) Mechanisms of action of pramipexole: putative neuroprotective effects. Rev Contemp Pharmacother 12: 33-57."},{"key":"10.1124\/jpet.103.062414_bib4","doi-asserted-by":"crossref","unstructured":"B\u00e9zard E, Brotchie JM, and Gross CE (2001) Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat Rev Neurosci 2: 577-587.","DOI":"10.1038\/35086062"},{"key":"10.1124\/jpet.103.062414_bib5","doi-asserted-by":"crossref","unstructured":"B\u00e9zard E, Ferry S, Mach Un Stark H, Leriche L, Boraud T, Gross C, and Sokoloff P (2003) Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. Nat Med 9: 762-767.","DOI":"10.1038\/nm875"},{"key":"10.1124\/jpet.103.062414_bib6","doi-asserted-by":"crossref","unstructured":"Blanchet PJ, Konitsiotis S, and Chase TN (1997) Motor response to a dopamine D3 receptor preferring agonist compared to apomorphine in levodopa-primed 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys. J Pharmacol Exp Ther 283: 794-799.","DOI":"10.1016\/S0022-3565(24)37098-3"},{"key":"10.1124\/jpet.103.062414_bib7","doi-asserted-by":"crossref","unstructured":"Blum D, Torch S, Lambeng N, Nissou MF, Benabid AL, Sadoul R, and Verna JM (2001) Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson\u2019s disease. Prog Neurobiol 65: 135-172.","DOI":"10.1016\/S0301-0082(01)00003-X"},{"key":"10.1124\/jpet.103.062414_bib8","doi-asserted-by":"crossref","unstructured":"Brunt ER, Brooks DJ, Korczyn AD, Montastruc JL, and Stocchi F (2002) A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson\u2019s disease not optimally controlled by l-DOPA. J Neural Transm 109: 489-502.","DOI":"10.1007\/s007020200040"},{"key":"10.1124\/jpet.103.062414_bib9","doi-asserted-by":"crossref","unstructured":"Carvey PM, McGuire SO, and Ling ZD (2001) Neuroprotective effects of D3 dopamine receptor agonists. Parkinsonism Relat Disord 7: 213-223.","DOI":"10.1016\/S1353-8020(00)00061-4"},{"key":"10.1124\/jpet.103.062414_bib10","doi-asserted-by":"crossref","unstructured":"Coldwell MC, Boyfield I, Brown T, Hagan JJ, and Middlemiss DN (1999) Comparison of the functional potencies of ropinirole and other dopamine receptor agonists at human D2(long), D3 and D4.4 receptors expressed in Chinese hamster ovary cells. Br J Pharmacol 127: 1696-1702.","DOI":"10.1038\/sj.bjp.0702673"},{"key":"10.1124\/jpet.103.062414_bib11","doi-asserted-by":"crossref","unstructured":"De Boer P and Abercrombie ED (1996) Physiological release of striatal acetylcholine in vivo: modulation by D1 and D2 dopamine receptor subtypes. J Pharmacol Exp Ther 277: 775-783.","DOI":"10.1016\/S0022-3565(25)12934-0"},{"key":"10.1124\/jpet.103.062414_bib12","doi-asserted-by":"crossref","unstructured":"Di Chiara G, Morelli M, and Consolo S (1994) Modulatory functions of neurotransmitters in the striatum: ACh\/dopamine\/NMDA interactions. Trends Neurosci 17: 228-233.","DOI":"10.1016\/0166-2236(94)90005-1"},{"key":"10.1124\/jpet.103.062414_bib13","doi-asserted-by":"crossref","unstructured":"Eden RJ, Costall B, Domeney AM, Gerrard PA, Harvey CA, Kelly ME, Naylor RJ, Owen DAA, and Wright A (1991) Preclinical pharmacology of ropinirole (SK&F 101468-A) a novel dopamine D2 agonist. Pharmacol Biochem Behav 38: 147-154.","DOI":"10.1016\/0091-3057(91)90603-Y"},{"key":"10.1124\/jpet.103.062414_bib14","doi-asserted-by":"crossref","unstructured":"Fox SH, Henry B, Hill MP, Crossman AR, and Brotchie JM (2002) Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson\u2019s disease. Mov Disord 17: 1180-1187.","DOI":"10.1002\/mds.10289"},{"key":"10.1124\/jpet.103.062414_bib15","doi-asserted-by":"crossref","unstructured":"Gerlach M and Riederer P (1996) Animal models of Parkinson\u2019s disease: an empirical comparison with the phenomenology of disease in man. J Neural Transm 103: 987-1041.","DOI":"10.1007\/BF01291788"},{"key":"10.1124\/jpet.103.062414_bib16","doi-asserted-by":"crossref","unstructured":"Gobert A, Di Cara B, Cistarelli L, and Millan MJ (2003) Piribedil enhances frontocortical and hippocampal release of acetylcholine in freely moving rats by blockade of \u03b12A-adrenoceptors: a dialysis comparison to talipexole and quinelorane in the absence of acetylcholinesterase inhibitors. J Pharmacol Exp Ther 305: 338-346.","DOI":"10.1124\/jpet.102.046383"},{"key":"10.1124\/jpet.103.062414_bib17","doi-asserted-by":"crossref","unstructured":"Ichikawa J, Dai J, O\u2019Laughlin IA, Fowler WL, and Meltzer HY (2002) Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum. Neuropsychopharmacology 26: 325-339.","DOI":"10.1016\/S0893-133X(01)00312-8"},{"key":"10.1124\/jpet.103.062414_bib18","doi-asserted-by":"crossref","unstructured":"Iida M, Miyazaki I, Tanaka KI, Kabuto H, Iwata-Ichikawa E, and Ogawa N (1999) Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist. Brain Res 838: 51-59.","DOI":"10.1016\/S0006-8993(99)01688-1"},{"key":"10.1124\/jpet.103.062414_bib19","doi-asserted-by":"crossref","unstructured":"Jenner P (2003) Oxidative stress in Parkinson\u2019s disease. Ann Neurol 53: S26-S38.","DOI":"10.1002\/ana.10483"},{"key":"10.1124\/jpet.103.062414_bib20","doi-asserted-by":"crossref","unstructured":"Joyce JN (1993) Differential response of striatal dopamine and muscarinic cholinergic receptor subtypes to the loss of dopamine: III. Results in Parkinson\u2019s disease cases. Brain Res 600: 156-160.","DOI":"10.1016\/0006-8993(93)90414-I"},{"key":"10.1124\/jpet.103.062414_bib21","doi-asserted-by":"crossref","unstructured":"Joyce JN (2001) Dopamine D3 receptor as a therapeutic target for antipsychotic and antiparkinson drugs. Pharmacol Ther 90: 231-259.","DOI":"10.1016\/S0163-7258(01)00139-5"},{"key":"10.1124\/jpet.103.062414_bib22","unstructured":"Joyce JN, Borwege S, and Millan MJ (2003a) Antioxidant effects of dopamine (DA) agonists mediate neuroprotection against DA in terminally differentiated SH-SY5Y cells (Abstract). Am Soc Neurosci 29: 733.10."},{"key":"10.1124\/jpet.103.062414_bib23","doi-asserted-by":"crossref","unstructured":"Joyce JN, Presgraves S, Renish L, Borwege S, Hagner D, Osredkar T, Replogle M, Paz Soldan MM, and Millan MJ (2003b) Neuroprotective effects of the novel D3\/D2 receptor agonist and antiparkinson agent S32504, in vitro against 1-methyl-4-phenylpyridinium (MPP+) and in vivo against 1-methyl-4-phenyl-1,2,2,6-tetrahydropyridine (MPTP): a comparison to ropinirole. Exp Neurol 184: 393-407.","DOI":"10.1016\/S0014-4886(03)00353-4"},{"key":"10.1124\/jpet.103.062414_bib24","doi-asserted-by":"crossref","unstructured":"Karasawa H, Taketo MM, and Matsui M (2003) Loss of anti-cataleptic effect of scopolamine in mice lacking muscarinic acetylcholine receptor subtype 4. Eur J Pharmacol 468: 15-19.","DOI":"10.1016\/S0014-2999(03)01642-X"},{"key":"10.1124\/jpet.103.062414_bib25","doi-asserted-by":"crossref","unstructured":"Koshikawa N, Kitamura M, Kobayashi M, and Cools AR (1996) Behavioural effects of 7-OH-DPAT are solely due to stimulation of dopamine D2 receptors in the shell of the nucleus accumbens: turning behaviour. Eur J Pharmacol 308: 235-241.","DOI":"10.1016\/0014-2999(96)00302-0"},{"key":"10.1124\/jpet.103.062414_bib26","doi-asserted-by":"crossref","unstructured":"Le WD, Jankovic J, Xie W, and Appel SH (2000) Antioxidant property of pramipexole independent of dopamine receptor activation in neuroprotection. J Neural Transm 107: 1165-1173.","DOI":"10.1007\/s007020070030"},{"key":"10.1124\/jpet.103.062414_bib27","doi-asserted-by":"crossref","unstructured":"Maratos EC, Jackson MJ, Pearce RK, and Jenner P (2001) Antiparkinson activity and dyskinesia risk of ropinirole and l-DOPA combination therapy in drug na\u00efve MPTP-lesioned common marmosets (Callithrix jacchus). Mov Disord 16: 631-641.","DOI":"10.1002\/mds.1149"},{"key":"10.1124\/jpet.103.062414_bib28","doi-asserted-by":"crossref","unstructured":"Marti M, Paganini F, Stocchi S, Mela F, Beani L, Bianchi C, and Morari M (2003) Plasticity of glutamatergic control of striatal acetylcholine release in experimental parkinsonism: opposite changes at group-II metabotropic and NMDA receptors. J Neurochem 84: 792-802.","DOI":"10.1046\/j.1471-4159.2003.01569.x"},{"key":"10.1124\/jpet.103.062414_bib29","doi-asserted-by":"crossref","unstructured":"Millan MJ, Brocco M, Papp M, Serres F, Drieu la Rochelle C, Sharp T, Peglion JL, and Dekeyne A (2004a) S32504, a novel naphtoxazine agonist at dopamine D3\/D2 receptors: III. Actions in models of potential antidepressive and anxiolytic activity in comparison to ropinirole. J Pharmacol Exp Ther 309: 936-950.","DOI":"10.1124\/jpet.103.062463"},{"key":"10.1124\/jpet.103.062414_bib30","doi-asserted-by":"crossref","unstructured":"Millan MJ, Cussac D, Gobert A, Lejeune A, Rivet JM, Mannoury La Cour C, Newman-Tancredi A, and Peglion JL. (2004b) S32504, a novel naphtoxazine agonist at dopamine D3\/D2 receptors: I. Cellular, electrophysiological and neurochemical profile in comparison to ropinirole. J Pharmacol Exp Ther 309: 903-920.","DOI":"10.1124\/jpet.103.062398"},{"key":"10.1124\/jpet.103.062414_bib31","doi-asserted-by":"crossref","unstructured":"Millan MJ, Dekeyne A, Rivet JM, Dubuffet T, Lavielle G, and Brocco M (2000) S33084, a novel, potent, selective and competitive antagonist at dopamine D3-receptors: II. Functional and behavioural profile compared with GR218,231 and L741,626. J Pharmacol Exp Ther 293: 1063-1073.","DOI":"10.1016\/S0022-3565(24)39333-4"},{"key":"10.1124\/jpet.103.062414_bib32","doi-asserted-by":"crossref","unstructured":"Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, and Newman-Tancredi A (2002) Differential actions of antiparkinsonian agents at multiple classes of monoaminergic receptor: I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther 303: 791-804.","DOI":"10.1124\/jpet.102.039867"},{"key":"10.1124\/jpet.103.062414_bib33","doi-asserted-by":"crossref","unstructured":"Millan MJ, Newman-Tancredi A, Brocco M, Gobert A, Lejeune F, Audinot V, Rivet JM, Schreiber R, Dekeyne A, Spedding M, et al. (1998) S18126 ({2-{4-(2,3-dihydrobenzo [1,4]dioxin-6-yl) piperazin-1-yl methyl] indan-2-yl): a potent, selective and competitive antagonist at dopamine D4 receptors: an in vitro and in vivo comparison to L745,870 (3-(4-[4-chlorophenyl]piperazin-1-yl)methyl-1H-pyrrolo [2,3b]pyridine) and raclopride. J Pharmacol Exp Ther 287: 167-186.","DOI":"10.1016\/S0022-3565(24)37777-8"},{"key":"10.1124\/jpet.103.062414_bib34","doi-asserted-by":"crossref","unstructured":"Millan MJ, Seguin L, Gobert A, Cussac D, Brocco M (2004c) The role of dopamine D3 as compared to D2 receptors in the control of locomotor activity: a combined behavioural and neurochemical analysis with novel, selective antagonists in rats. Psychopharmacology, in press.","DOI":"10.1007\/s00213-003-1770-x"},{"key":"10.1124\/jpet.103.062414_bib35","doi-asserted-by":"crossref","unstructured":"Morissette M, Goulet M, Grondin R, Blanchet P, B\u00e9dard PJ, Di Paolo T, and L\u00e9vesque D (1998) Associative and limbic regions of monkey striatum express high levels of dopamine D3 receptors: effects of MPTP and dopamine agonist replacement therapies. Eur J Neurosci 10: 2565-2573.","DOI":"10.1046\/j.1460-9568.1998.00264.x"},{"key":"10.1124\/jpet.103.062414_bib36","doi-asserted-by":"crossref","unstructured":"Nair VD, Olanow W, and Sealfon SC (2003) Activation of phosphoinosidite 3-kinase by D2 receptor presents apoptosis in dopaminergic cell lines, Biochem J 73: 25-32.","DOI":"10.1042\/bj20030017"},{"key":"10.1124\/jpet.103.062414_bib37","doi-asserted-by":"crossref","unstructured":"Newman-Tancredi A, Cussac D, Audinot V, Nicolas JP, De Ceuninck F, Boutin JA, and Millan MJ (2002) Differential actions of antiparkinsonian agents at multiple classes of monoaminergic receptor: II. Agonist and antagonist properties at subtypes of dopamine D2-like receptor and \u03b11\/\u03b12-adrenoceptor. J Pharmacol Exp Ther 303: 805-814.","DOI":"10.1124\/jpet.102.039875"},{"key":"10.1124\/jpet.103.062414_bib38","doi-asserted-by":"crossref","unstructured":"Newman-Tancredi A, Cussac D, Brocco M, Rivet JM, Chaput C, Touzard M, Pasteau V, and Millan MJ (2001) Dopamine D2 receptor-mediated G-protein activation in rat striatum: functional autoradiography and influence of unilateral 6-hydroxydopamine lesions of the substantia nigra. Brain Res 920: 41-54.","DOI":"10.1016\/S0006-8993(01)02927-4"},{"key":"10.1124\/jpet.103.062414_bib39","doi-asserted-by":"crossref","unstructured":"Pearce RK, Banerji T, Jenner P, and Marsden CD (1998) De novo administration of ropinirole and bromocriptine induces less dyskinesia than l-DOPA in the MPTP-treated marmoset. Mov Disord 13: 234-241.","DOI":"10.1002\/mds.870130207"},{"key":"10.1124\/jpet.103.062414_bib40","doi-asserted-by":"crossref","unstructured":"Quik M, Police S, He L, Di Monte DA, and Langston JW (2000) Expression of D3 receptor messenger RNA and binding sites in monkey striatum and substantia nigra after nigrostriatal degeneration: effect of levodopa treatment. Neuroscience 98: 263-273.","DOI":"10.1016\/S0306-4522(00)00130-5"},{"key":"10.1124\/jpet.103.062414_bib41","doi-asserted-by":"crossref","unstructured":"Ramirez AD, Wong SKF, and Menniti FS (2003) Pramipexole inhibits MPTP toxicity in mice by dopamine D3 receptor dependent and independent mechanisms. Eur J Pharmacol 475: 29-35.","DOI":"10.1016\/S0014-2999(03)02087-9"},{"key":"10.1124\/jpet.103.062414_bib42","doi-asserted-by":"crossref","unstructured":"Rascol O, Payoux P, Ory F, Ferreira JJ, Brefel-Courbon C, and Montastruc JL (2003) Limitations of current Parkinson\u2019s disease therapy. Ann Neurol 53: S3-S15.","DOI":"10.1002\/ana.10513"},{"key":"10.1124\/jpet.103.062414_bib43","doi-asserted-by":"crossref","unstructured":"Raz A, Feingold A, Zelanskaya V, Vaadia E, and Bergman H (1996) Neuronal synchronization of tonically active neurons in the striatum of normal and parkinsonian primates. J Neurophysiol 76: 2083-2088.","DOI":"10.1152\/jn.1996.76.3.2083"},{"key":"10.1124\/jpet.103.062414_bib44","doi-asserted-by":"crossref","unstructured":"Sato K, Ueda H, Okumura F, and Misu Y (1994) Supersensitization of intrastriatal dopamine receptors involved in opposite regulation of acetylcholine release in Parkinson\u2019s model rats. Neurosci Lett 173: 59-62.","DOI":"10.1016\/0304-3940(94)90149-X"},{"key":"10.1124\/jpet.103.062414_bib45","doi-asserted-by":"crossref","unstructured":"Schapira AH and Olanow CW (2003) Rationale for the use of dopamine agonists as neuroprotective agents in Parkinson\u2019s disease. Ann Neurol 53: S149-S159.","DOI":"10.1002\/ana.10514"},{"key":"10.1124\/jpet.103.062414_bib46","unstructured":"Silverdale MA, Millan MJ, Crossman AR, and Brotchie JM (2002) Dopamine D3 receptor blockade and not stimulation, is associated with anti-parkinsonian activity in the MPTP-lesioned, non-human primate model of Parkinson\u2019s disease. Neurology 58: 493-494."},{"key":"10.1124\/jpet.103.062414_bib47","doi-asserted-by":"crossref","unstructured":"Skalisz LL, Beijamini V, Joca SL, Vital MA, Da Cunha C, and Andreatini R (2002) Evaluation of the face validity of reserpine administration as an animal model of depression-Parkinson\u2019s disease association. Prog Neuropsychopharmacol Biol Psychiatry 26: 879-883.","DOI":"10.1016\/S0278-5846(01)00333-5"},{"key":"10.1124\/jpet.103.062414_bib48","doi-asserted-by":"crossref","unstructured":"Smith LA, De Salvia M, Jenner P, and Marsden CD (1996) An appraisal of the antiparkinsonian activity of piribedil in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets. Mov Disord 11: 125-135.","DOI":"10.1002\/mds.870110203"},{"key":"10.1124\/jpet.103.062414_bib49","doi-asserted-by":"crossref","unstructured":"Van Kampen JM and Stoessl AJ (2003) Effects of oligonucleotide antisense to dopamine D3 receptor mRNA in a rodent model of behavioural sensitization to levo-dopa. Neuroscience 116: 307-314.","DOI":"10.1016\/S0306-4522(02)00548-1"},{"key":"10.1124\/jpet.103.062414_bib50","doi-asserted-by":"crossref","unstructured":"Whone AL, Watts RL, Stoessl AJ, Davis M, Reske S, Nahmias C, Lang AE, Rascol O, Ribeiro MJ, Remy P, et al. (2003) Slower progression of Parkinson\u2019s disease with ropinirole vs levodopa: the REAL-PET study. Ann Neurol 54: 93-101.","DOI":"10.1002\/ana.10609"},{"key":"10.1124\/jpet.103.062414_bib51","doi-asserted-by":"crossref","unstructured":"Yamada S, Harano M, Annoh N, and Tanaka M (1999) Dopamine D3 receptors modulate evoked dopamine release from slices of rat nucleus accumbens via muscarinic receptors, but not from the striatum. J Pharmacol Exp Ther 291: 994-998.","DOI":"10.1016\/S0022-3565(24)35201-2"},{"key":"10.1124\/jpet.103.062414_bib52","doi-asserted-by":"crossref","unstructured":"Zarrindast MR and Minaian A (1991) Different effects of direct and indirect dopamine receptor agonists on immobility time in reserpine-treated mice. Gen Pharmacol 22: 1017-1021.","DOI":"10.1016\/0306-3623(91)90571-M"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524313576?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524313576?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.103.062414","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T20:53:09Z","timestamp":1739998389000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524313576"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,6]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2004,6]]}},"alternative-id":["S0022356524313576"],"URL":"https:\/\/doi.org\/10.1124\/jpet.103.062414","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2004,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"S32504, a Novel Naphtoxazine Agonist at Dopamine D3\/D2 Receptors: II. Actions in Rodent, Primate, and Cellular Models of Antiparkinsonian Activity in Comparison to Ropinirole","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.103.062414","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2004 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}